FDA Approved: SYNJARDY — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for SYNJARDY, the fixed-dose combination of empagliflozin and metformin hydrochloride, submitted by Boehringer Ingelheim…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• SYNJARDY (empagliflozin and metformin hydrochloride)

Snippet

SUPPL AP for SYNJARDY (EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE)